These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26099742)

  • 21. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
    Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
    Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood.
    van Beek RD; van den Heuvel-Eibrink MM; Laven JS; de Jong FH; Themmen AP; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Pieters R; de Muinck Keizer-Schrama SM
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3869-74. PubMed ID: 17726078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
    Badawy A; Elnashar A; El-Ashry M; Shahat M
    Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Fréour T; Barrière P; Masson D
    Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
    Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer].
    Krawczuk-Rybak M; Leszczyńska E; Wysocka J; Zelazowska-Rutkowska B
    Pediatr Endocrinol Diabetes Metab; 2008; 14(2):99-103. PubMed ID: 18721496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).
    Clowse ME; Copland SC; Hsieh TC; Chow SC; Hoffman GS; Merkel PA; Spiera RF; Davis JC; McCune WJ; Ytterberg SR; St Clair EW; Allen NB; Specks U; Stone JH;
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1777-81. PubMed ID: 22127969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
    Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
    Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments.
    Silva C; Ribeiro Rama AC; Reis Soares S; Moura-Ramos M; Almeida-Santos T
    J Ovarian Res; 2019 Oct; 12(1):102. PubMed ID: 31672154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
    Whitehead J; Toledo MG; Stern CJ
    Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.
    Yoo C; Yun MR; Ahn JH; Jung KH; Kim HJ; Kim JE; Park JY; Park KO; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):565-75. PubMed ID: 23842722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy.
    Decanter C; Cloquet M; Dassonneville A; D'Orazio E; Mailliez A; Pigny P
    Reprod Biomed Online; 2018 Jun; 36(6):711-718. PubMed ID: 29523398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
    Henry NL; Xia R; Schott AF; McConnell D; Banerjee M; Hayes DF
    Oncologist; 2014 Jan; 19(1):68-74. PubMed ID: 24319018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
    Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
    Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients.
    Del Mastro L; Catzeddu T; Boni L; Bell C; Sertoli MR; Bighin C; Clavarezza M; Testa D; Venturini M
    Ann Oncol; 2006 Jan; 17(1):74-8. PubMed ID: 16254024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.
    Oostra DR; Lustberg MB; Reinbolt RE; Pan X; Wesolowski R; Shapiro CL
    Mol Cell Endocrinol; 2015 Feb; 402():51-6. PubMed ID: 25575458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Müllerian Hormone in Female Adolescent Cancer Patients Before, During, and After Completion of Therapy: A Pilot Feasibility Study.
    Gupta AA; Lee Chong A; Deveault C; Traubici J; Maloney AM; Knight S; Lorenzo A; Allen L
    J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):599-603. PubMed ID: 27184535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment.
    Janse F; Donnez J; Anckaert E; de Jong FH; Fauser BC; Dolmans MM
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1136-44. PubMed ID: 21289248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
    Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
    Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.